HD-OPM Archive
Hashtags

#reverse

88 posts

Six RCTs have shown diet can reverse plaque, and none used a purely vegan diet

Oct 24, 2025 · Louis Nervegna ♥ 38 · 💬 29 Plaque, CAC & CT angiography

Louis pushes back on claims that only vegan diets reverse plaque. He lists the only six randomized diet trials showing plaque reversal (Lifestyle Heart, STARS, SCRIP, PREDIMED, CORDIOPREV, DISCO), all primarily plant-based but none strictly vegan (even Ornish allowed egg whites and non-fat dairy), and summarizes the common foods they emphasized and limited.

DISCO-CT: DASH diet plus statins reversed ~40 mm3 of soft plaque in a year on CT

Aug 12, 2026 · Louis Nervegna ♥ 38 · 💬 21 Plaque, CAC & CT angiography

In the DISCO-CT randomized trial, a DASH-style diet with statins reduced non-calcified plaque volume by 39.5 mm3 (adjusted to one year from 66 weeks), the largest dietary regression on CT angiography to date. An at-risk person typically grows about 5 mm3 per year, so this equals roughly 8 years of progression. DASH fat was ~30% of calories, mostly unsaturated.

Norwegian 4x4 intervals: Rhonda Patrick on reversing heart aging and raising VO2 max

Oct 04, 2025 · Gokhan Can ♥ 27 · 💬 29 Exercise & fitness

Summarises a Rhonda Patrick video: moderate exercise is ineffective for many, so vigorous HIIT such as the Norwegian 4x4 (four 4-minute efforts at about 80-90% max heart rate with 4-minute recovery) improves VO2 max. She cites a two-year study that reversed about 20 years of cardiac aging in sedentary 50-year-olds, and exercise reducing glycation-driven heart stiffness (Asif et al., PNAS 2000).

Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff)

May 11, 2025 · Louis Nervegna ♥ 20 · 💬 37 ↩ 9 Plaque, CAC & CT angiography

Louis highlights a Budoff-led CCTA trial in which low-dose colchicine reduced percent atheroma volume by over 1% in a year, with lower CRP and a slowing of calcified plaque. He contrasts this with the Keto-CTA study, where PAV rose 0.8% on a keto diet. Budoff notes it was a small study but supports colchicine in chronic stable coronary disease.

Intensive statin reversed atherosclerosis on IVUS in a 2004 Cleveland Clinic-led trial

Dec 23, 2023 · Louis Nervegna ♥ 20 · 💬 40 ↩ 12 Plaque, CAC & CT angiography

Louis shares a Cleveland Clinic video to counter the claim that statins do not reverse plaque. The 2004 trial used intravascular ultrasound (IVUS), which he calls the gold standard for plaque imaging, and showed regression with high-dose statin driving LDL-C down to about 60 mg/dL. He stresses LDL must be very low to achieve regression.

Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18%

Sep 13, 2025 · Louis Nervegna ♥ 19 · 💬 23 ↩ 21 Plaque, CAC & CT angiography

Summary of the Japan-ACS trial, in which over 300 acute coronary syndrome patients were randomized to pitavastatin or atorvastatin and imaged with IVUS. Both statins produced similar, substantial regression of non-culprit plaque volume as LDL fell into the 80s mg/dL, which is one reason statins remain standard care after ACS.

Case report: 10 mg atorvastatin cleared most of a severe LAD blockage over 4 years

Oct 06, 2025 · Louis Nervegna ♥ 29 · 💬 14 Statins

Responding to influencers who say plaque cannot be reversed with statins, Louis cites a case report in which a patient taking low-dose atorvastatin went from a severe to a mild LAD narrowing, documented on CT angiography. It is a single case, but illustrates that statin-associated plaque regression can occur.

Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS

Jan 18, 2025 · Louis Nervegna ♥ 10 · 💬 29 ↩ 9 Plaque, CAC & CT angiography

Louis lists human trials in which statins reversed or halted atheroma growth measured as percent atheroma volume (PAV). High-dose atorvastatin and rosuvastatin regressed PAV in SATURN and ASTEROID, while REVERSAL showed halted progression versus pravastatin. COSMOS added canakinumab to rosuvastatin, and PROSPECT and JAPAN-ACS showed lower progression on statins.

DISCO-CT: DASH diet plus statins reversed soft plaque by about 40 mm3 in a year

Aug 18, 2025 · Louis Nervegna ♥ 22 · 💬 12 ↩ 25 Plaque, CAC & CT angiography

Louis describes the DISCO-CT randomized trial, where a DASH-style diet with statins produced the largest soft plaque regression (NCPV) on CT angiography of any diet trial, -39.5 mm3 adjusted to one year. He puts this against about 5 mm3/year typical progression, with the caveat that this is relative to a typical American, not the patients' own history.

Esselstyn's 'cure' angiogram overstates diet effect: baseline followed a heart attack

Nov 13, 2026 · Louis Nervegna ♥ 19 · 💬 17 Mediterranean, DASH, MIND & plant-forward diets

Louis critiques the angiogram of Esselstyn's patient Joseph Crowe, often cited as proof that diet cures heart disease. The baseline image came directly after a heart attack and showed plaque plus thrombus and vasospasm, so later opening of the artery reflects natural healing as well as diet. He also notes Crowe died at 72, about 28 years after a heart attack at 44.

Exercise, including HIIT, can reduce coronary plaque burden and add to LDL lowering

Jul 10, 2025 · Louis Nervegna ♥ 25 · 💬 17 ↩ 8 Plaque, CAC & CT angiography

A shared review states that regular moderate-to-high intensity exercise reduces coronary plaque burden in CAD patients, with HIIT and moderate continuous training both leading to regression. Combining exercise with aggressive LDL control below 70 mg/dL gives additive benefit, while extreme volumes may increase calcification though with more stable plaque.

Six RCTs show statins reverse total plaque volume by 5% to 17%

Aug 25, 2026 · Louis Nervegna ♥ 27 · 💬 9 ↩ 1 Plaque, CAC & CT angiography

Louis lists six randomized trials showing reversal of total atheroma volume with statins: COSMOS ~5%, SATURN ~5.5%, ASTEROID ~6.5%, IBIS-4 ~7.5%, STABLE ~8%, JAPAN-ACS ~17%. Reversals were measured by CT angiography or IVUS and came from soft rather than calcified plaque. A shared chart relates LDL to TAV change across statin, PCSK9 and ezetimibe trials.

YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks

Aug 15, 2026 · Louis Nervegna ♥ 16 · 💬 19 Plaque, CAC & CT angiography

The YELLOW study found that short-term intensive lipid lowering with rosuvastatin reduced lipid-core burden (yellow plaque) in coronary lesions in as little as 7-8 weeks, stabilizing vulnerable plaque rather than shrinking blockages. YELLOW III added the PCSK9 inhibitor evolocumab to statins with greater improvement in plaque composition. Generic rosuvastatin costs under $10/month.

CORDIOPREV: Mediterranean diet shrank carotid plaque and cut recurrent events about 25%

Mar 28, 2024 · Louis Nervegna ♥ 17 · 💬 13 ↩ 27 Mediterranean, DASH, MIND & plant-forward diets

Louis summarizes CORDIOPREV, an RCT of 1002 coronary patients comparing a Mediterranean diet rich in extra virgin olive oil with a low-fat diet. The Mediterranean diet reduced carotid intima-media thickness at 5 and 7 years while the low-fat diet showed no change, and also lowered carotid plaque height. He also cites roughly 25% fewer recurrent major cardiovascular events over 7 years, with benefits seen despite statin treatment and mean LDL-C below 90.

FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months

Oct 31, 2026 · Louis Nervegna ♥ 25 · 💬 11 Plaque, CAC & CT angiography

Louis highlights the randomized FLOWPROMOTE trial in 104 statin-naive patients with coronary artery disease, scanned by CT angiography at baseline, 9 and 18 months. Rosuvastatin 40 mg plus ezetimibe 10 mg lowered LDL-C to 42.5 mg/dL versus 69.5 mg/dL with atorvastatin 40 mg and reduced total plaque volume by about 21%. The shared write-up frames this as evidence that coronary atherosclerosis can be reversed with intensive lipid lowering.

Six strategies shown to regress plaque in human randomized trials

Feb 27, 2025 · Louis Nervegna ♥ 27 · 💬 10 ↩ 3 Plaque, CAC & CT angiography

Louis lists strategies with RCT evidence for plaque regression: major weight loss, a Mediterranean or DASH diet, LDL-lowering drugs, colchicine, exercise and high-dose EPA. He notes six RCTs show diet can regress plaque and that Ornish's results resembled PREDIMED and CORDIOPREV, while Esselstyn's data are not from RCTs.

Can fasting reverse plaque? Autophagy makes it plausible but evidence is indirect

Jun 29, 2026 · Louis Nervegna ♥ 23 · 💬 14 Fasting & meal timing

Louis argues there is biological plausibility that fasting could clear damaged arterial tissue via autophagy, linking earlier posts. He cites the 2010 DIRECT-Carotid trial showing large weight loss can regress carotid atherosclerosis, and a shared post on a Nature Metabolism 7-day fast study in 12 people with a day-3 shift in about 1,000 proteins. Direct evidence for plaque reversal by fasting is anecdotal.

Six randomized diet trials showed plaque reversal, from Ornish to CORDIOPREV and DISCO

Oct 16, 2024 · Louis Nervegna ♥ 32 · 💬 5 ↩ 11 Plaque, CAC & CT angiography

Louis lists the only six human RCTs in which diet reversed plaque: Lifestyle Heart Trial (Ornish diet), STARS and SCRIP (AHA diet), PREDIMED, CORDIOPREV (Mediterranean) and DISCO (DASH-style). Successful diets emphasized produce, legumes, whole grains, nuts, olive oil, fish and some dairy. They limited junk food, refined grains, butter, fatty red meat and heavy alcohol. He links each paper.

About 95% of acute-thrombosis heart attacks involve soft plaque, not calcified plaque

Oct 03, 2026 · Louis Nervegna ♥ 9 · 💬 9 Plaque, CAC & CT angiography

The post says about 64% of heart attacks from acute thrombosis come from rupture of soft lipid-rich plaque and about 25% from erosion of soft plaque, while only about 5% involve calcified nodules. Because statins and other lipid-lowering drugs stabilize and reverse soft plaque, the poster argues they address the plaque type most responsible for heart attacks.

FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43

Oct 31, 2026 · Louis Nervegna ♥ 14 · 💬 4 Plaque, CAC & CT angiography

Louis adds FLOWPROMOTE to the pile of randomized trials showing statins reverse soft and total plaque. In 104 statin-naive stable CAD patients on CT angiography, LDL around 70 mg/dL gave a 13.6% total plaque reduction and around 43 mg/dL gave 21.1%, with 90% of the lower-LDL group showing regression. The linear LDL-to-regression relationship supports LDL being causal in atherosclerosis.

FLOWPROMOTE: rosuvastatin plus ezetimibe vs atorvastatin for plaque regression

Nov 07, 2026 · Louis Nervegna ♥ 13 · 💬 5 Plaque, CAC & CT angiography

Louis shares an explainer of FLOWPROMOTE, a 2026 JAMA Cardiology randomized trial in 104 Danish adults with stable coronary disease and no prior statin. Participants received atorvastatin 40 mg or rosuvastatin 40 mg plus ezetimibe 10 mg for 18 months with serial coronary CT angiography. It also explains how LDL drives plaque and why combining drugs lowers LDL further.

Case: carotid plaque regression with salmon, niacin and low-dose rosuvastatin

Dec 23, 2023 · Louis Nervegna ♥ 13 · 💬 3 Plaque, CAC & CT angiography

Louis shares a video by Dr. Ford Brewer describing his own plaque reversal. He ate salmon daily, added niacin and low-dose rosuvastatin and switched from an ARB to an ACE inhibitor, with a major decrease in carotid plaque volume and CIMT arterial age falling from 72 to 52. It is a single self-reported case in a video from a clinic that also sells services and supplements.

Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study

Apr 09, 2025 · Louis Nervegna ♥ 8 · 💬 2 Plaque, CAC & CT angiography

Louis compares non-calcified plaque volume (NCPV) changes in the Keto-CTA (LMHR) study with a second Matthew Budoff study in higher-risk people whose LDL was lowered to about 30 mg/dL with the PCSK9 inhibitor Repatha. The lean, healthy keto group with LDL 254 mg/dL progressed, while the hypertensive, higher-risk Repatha group mostly showed major regression. He also notes that uL and mm^3 are the same unit when comparing NCPV across studies.

Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30

Nov 13, 2026 · Louis Nervegna ♥ 9 · 💬 1 PCSK9, ezetimibe & newer drugs

Louis explains a small uncontrolled study of the PCSK9 inhibitor evolocumab with CT angiography. Average LDL was about 30 mg/dL, 37 of 47 patients had some non-calcified plaque regression, and many had large reversals worth years of typical growth (about 5 mm3 per year). He cautions it was small with no randomization or control group, and that PCSK9 monotherapy is not yet proven to reduce heart attacks.

CORDIOPREV: Mediterranean diet reversed carotid plaque and cut recurrent events ~25%

Apr 13, 2025 · Louis Nervegna ♥ 14 Plaque, CAC & CT angiography

Louis summarizes the 2021 CORDIOPREV RCT in patients with prior heart attack or stroke on standard medical care: a Mediterranean diet rich in olive oil, nuts and fish reduced carotid thickness at 5 and 7 years, unlike a low-fat diet, and reduced maximum plaque height. Recurrent major cardiovascular events were roughly 25% lower, even though participants were already on statins and other drugs.

Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL

Oct 31, 2026 · Louis Nervegna ♥ 12 ↩ 1 Plaque, CAC & CT angiography

Louis shares a chart of randomized trials showing plaque reversal with statins, ezetimibe and PCSK9 inhibitors, with total atheroma volume change plotted against LDL-C. Total plaque reversal ranged from about 5% to 17% in six older statin trials, measured by CT angiography or IVUS, and came from soft rather than calcified plaque. The chart suggests total plaque reversal begins once LDL falls below roughly 90 mg/dL.

DISCO-CT: DASH diet plus statins reversed ~40 mm3 of soft plaque in one year

Nov 14, 2026 · Louis Nervegna ♥ 6 Plaque, CAC & CT angiography

Louis explains the DISCO-CT randomized trial, where a DASH diet plus statins produced the largest soft (non-calcified) plaque regression of any dietary trial on CT angiography. Adjusted to one year it was -39.5 mm3, versus an average at-risk person growing about 5 mm3 per year, so roughly 8 years of progression reversed. He notes the DASH diet was about 30% fat, mostly unsaturated, and adds caveats about interpretation.

A rising calcium score on a statin does not mean it failed, per FLOWPROMOTE details

Nov 08, 2026 · Louis Nervegna ♥ 1 Plaque, CAC & CT angiography

Louis shares a cardiologist's explanation that a higher calcium score on a statin neither proves failure nor success, since plaque picks up calcium as it hardens and denser calcium counts extra. It summarizes FLOWPROMOTE: atorvastatin 40 mg vs rosuvastatin 40 mg plus ezetimibe 10 mg lowered LDL more and shrank total plaque more in 18 months while calcified plaque grew in both groups. These were secondary results of a small trial on CT, not event outcomes.